


Supplemental tables:


- Figure e-1 Functional outcomes and vascular endpoints of patients with ischemic stroke who
 have undergone thrombolysis by study
- Figure e-2 Functional outcomes and vascular endpoints of patients with ischemic stroke without thrombolysis (Headpost study)
- Figure e-3 Functional outcomes and vascular endpoints of patients with stroke by study
- Figure e-4 Odds ratio of being prescribed preventatives on admission and at 90-day follow up by study
- Figure e-5 Functional outcomes and vascular endpoints of patients with ischemic stroke by study
- Figure e-6 Functional outcomes and vascular endpoints of patients with intracerebral hemorrhage by study
- Figure e-7 Health related quality of life outcomes categorised into the five dimensions of EQ5D stratified by study
- Figure e-8 Ischemic stroke health related quality of life outcomes categorised into the five dimensions of EQ5D stratified by study
- Figure e-9 Intracerebral hemorrhage health related quality of life outcomes categorised into the five dimensions of EQ5D stratified by study
- Figure e-10 Hospital management by sex









Outcome	Women n/N	Men n/N		ES (95% CI)	Р
MEDICATION O	N ADMISSION				
Antihypertensiv	e agents				
ENCHANTED	649/1245	849/2043	-	1.08 (0.85, 1.37)	0.524
HEADPOST	2454/4429	3165/6664		1.24 (1.13, 1.35)	< 0.000
INTERACT	574/1191	875/2039	-	1.24 (1.04, 1.48)	0.018
Subtotal (I-squa	red = 0.0%, p =	0.559)	\Q	1.22 (1.13, 1.31)	
Anticoagulants					
ENCHANTED	32/1245	50/2040		0.78 (0.47, 1.30)	0.338
HEADPOST	430/4419	521/6656		1.00 (0.86, 1.18)	0.966
INTERACT	29/1191	56/2039		0.81 (0.49, 1.34)	0.415
Subtotal (I-squa	red = 0.0%, p =	0.507)	\rightarrow	0.97 (0.84, 1.12)	
Antiplatelets					
ENCHANTED	200/4245	456/2040	-	0.83 (0.68, 1.02)	0.079
HEADPOST	296/1245 2120/4429	3507/6664		0.86 (0.78, 0.95)	0.002
INTERACT	96/1191	201/2042	-	0.87 (0.65, 1.17)	0.360
Subtotal (I-squa				0.86 (0.79, 0.93)	0.000
Glucose lowering	na aante				
ENCHANTED		243/2040		0.98 (0.75, 1.27)	0.860
HEADPOST	173/1245 840/4429	1383/6664		0.85 (0.77, 0.95)	0.003
INTERACT		148/2039		, , ,	0.003
Subtotal (I-squa	63/1191 red = 0.0%, p =		\Diamond	0.74 (0.54, 1.02) 0.86 (0.78, 0.94)	0.068
Lipid lowering a	nante				
ENCHANTED	252/1245	363/2039	-	0.88 (0.71, 1.10)	0.268
HEADPOST	948/4429	1348/6664		0.83 (0.74, 0.93)	0.200
INTERACT	69/1191	140/2039			0.784
			\Diamond	0.95 (0.67, 1.35)	0.764
Subtotal (I-squa SECONDARY PI		,	•	0.85 (0.77, 0.94)	
Antihypertensiv					
ENCHANTED	-	4407/4000	+	0.98 (0.80, 1.19)	0.814
HEADPOST	723/1090	1107/1806	-	0.91 (0.82, 1.02)	0.106
INTERACT	2162/3317	3317/5329		0.85 (0.65, 1.12)	0.256
Subtotal (I-squa	805/928 red = 0.0%, p =	1343/1535 0.718)	0	0.92 (0.84, 1.01)	0.200
Aspirin					
ENCHANTED	862/1089	1525/1808	-	0.89 (0.70, 1.13)	0.331
HEADPOST	1926/3288	3162/5299	•	1.02 (0.92, 1.13)	0.710
Subtotal (I-squa			₫	1.00 (0.90, 1.10)	0.710
NOTE: Weights a	are from random	effects analysis	s		
		1	-		
	.005	.02	.5 1	5	
	More likely	prescribed to	men	More likely prescribed to	women







Outcome	Women n/N	Men n/N		ES (95% CI)	Р
EQ-5D usual ac	tivities				
SCAST	353/641	365/856	-	1.41 (1.11, 1.80)	0.0056
ENCHANTED	565/1086	801/1800	-=-	1.27 (1.04, 1.53)	0.0161
HEADPOST	1649/2952	2086/4772	-	1.28 (1.15, 1.44)	<0.001
Subtotal (I-squared = 0.0% , p = 0.865)			◊	1.30 (1.19, 1.42)	
EQ-5D anxiety/o	denression				
SCAST	268/641	254/852		1.65 (1.30, 2.10)	<0.001
ENCHANTED	376/1081	469/1793	-	1.39 (1.15, 1.68)	
HEADPOST	950/2948	1120/4760	-	1.33 (1.17, 1.50)	
Subtotal (I-squa			\Q	1.40 (1.25, 1.57)	
	20.070, p	0.200)	*	(26,)	
EQ-5D self-care)				
SCAST	259/642	244/856	+=-	1.23 (0.94, 1.61)	
ENCHANTED	416/1086	562/1801	-	1.21 (0.99, 1.48)	
HEADPOST	1209/2952	1421/4771		1.31 (1.16, 1.47)	
Subtotal (I-squa	red = 0.0%, p :	= 0.738)	\Q	1.28 (1.16, 1.40)	
EQ-5D mobility					
SCAST	381/642	362/858	-	1.53 (1.21, 1.94)	0.0005
ENCHANTED	516/1086	737/1801	╆-	1.11 (0.92, 1.35)	
HEADPOST	1408/2952	1651/4770	-	1.32 (1.17, 1.47)	
Subtotal (I-squa	red = 48.0%, p	= 0.146)	\Diamond	1.30 (1.11, 1.51)	
EQ-5D pain/disc	comfort				
SCAST	324/643	344/857		1.35 (1.07, 1.69)	0.0099
ENCHANTED	341/1083	457/1799	-	1.18 (0.98, 1.43)	
HEADPOST	1068/2951	1377/4762	-	1.19 (1.06, 1.33)	
Subtotal (I-squa			\Diamond	1.21 (1.10, 1.32)	
NOTE: Weights	·	,	sis	,	
	ı	1			
.00	5 .02	.5	1	5	

Worse in men Worse in women

